Nyxoah's (NYXH) "Sell (D-)" Rating Reiterated at Weiss Ratings

Key Points

• Nyxoah (NASDAQ: NYXH) has had its rating reaffirmed as "sell (D-)" by Weiss Ratings, indicating ongoing concerns about its stock performance.
• The company reported a loss of ($0.63) earnings per share, just missing analysts' estimates, along with revenue exceeding expectations at $1.58 million.
• Nyxoah's stock currently has a market capitalization of $207.77 million and a 12-month trading range with a low of $4.34 and a high of $11.87.

Nyxoah (NASDAQ:NYXH - Get Free Report)'s stock had its "sell (d-)" rating restated by equities research analysts at Weiss Ratings in a report issued on Wednesday,Weiss Ratings reports.

Nyxoah Stock Performance

NYXH opened at $6.10 on Wednesday. The firm has a market capitalization of $207.77 million, a P/E ratio of -2.65 and a beta of 1.53. The stock's 50 day moving average price is $5.92 and its two-hundred day moving average price is $6.76. The company has a quick ratio of 2.38, a current ratio of 2.63 and a debt-to-equity ratio of 0.29. Nyxoah has a 12-month low of $4.34 and a 12-month high of $11.87.

Nyxoah (NASDAQ:NYXH - Get Free Report) last released its earnings results on Monday, August 18th. The company reported ($0.63) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.62) by ($0.01). The business had revenue of $1.58 million during the quarter, compared to analyst estimates of $1.33 million. Nyxoah had a negative net margin of 1,541.84% and a negative return on equity of 79.18%. On average, equities analysts forecast that Nyxoah will post -1.91 earnings per share for the current year.

Institutional Trading of Nyxoah

Hedge funds have recently modified their holdings of the company. Bank of America Corp DE lifted its position in shares of Nyxoah by 72.4% in the 2nd quarter. Bank of America Corp DE now owns 7,866 shares of the company's stock worth $59,000 after acquiring an additional 3,303 shares during the period. Raymond James Financial Inc. bought a new stake in shares of Nyxoah in the 2nd quarter worth approximately $70,000. Kovack Advisors Inc. lifted its position in shares of Nyxoah by 16.5% in the 1st quarter. Kovack Advisors Inc. now owns 23,295 shares of the company's stock worth $163,000 after acquiring an additional 3,295 shares during the period. Shay Capital LLC bought a new stake in shares of Nyxoah in the 2nd quarter worth approximately $374,000. Finally, Franklin Resources Inc. lifted its position in shares of Nyxoah by 0.9% in the 2nd quarter. Franklin Resources Inc. now owns 294,990 shares of the company's stock worth $2,207,000 after acquiring an additional 2,655 shares during the period.

About Nyxoah

Nyxoah SA, a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company's lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.